GAMRIC 2026: Amprologix heads to Lisbon
1 October 2026In September 2026, the whole Amprologix team travelled to Lisbon for GAMRIC 2026: the Global Antimicrobial Resistance Innovators Conference, organised…
In September 2026, the whole Amprologix team travelled to Lisbon for GAMRIC 2026: the Global Antimicrobial Resistance Innovators Conference, organised…
We are pleased to share the publication of a new peer-reviewed study in the Journal of Antimicrobial Chemotherapy – Antimicrobial…
From 17th-22nd April, Mat and Vicky headed to Munich, Germany for ESCMID GLOBAL 2026
Last week, CSO Mat Upton and CEO Gordon Barker travelled to Basel, Switzerland for the BEAM Alliance 10th AMR meeting.…
On 14th December, CSO Mat Upton was invited to attend the Final Forum of the Saudi Biotechnology Accelerator (SBA) in…
Having been based in the Marine Building at Plymouth University for the last 2-years, the company is now moving to the Derriford Research Facility to accommodate our expansion plans as we transition into the clinical phase of our antibiotic discovery programmes.
Amprologix CSO collaborates with Dr Max Ryadnov from the UK’s National Physical Laboratory, to publish new data on the novel mode of action of epidermicin NI01. Findings are reported in the August issue of iScience.
